Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer
Trilaciclib is a recently approved cyclin-dependent kinase 4/6 inhibitor that is designed to decrease the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small-cell lung cancer receiving chemotherapy. Currently, this first-in-class therapy raises two open is...
| Published in: | Translational Oncology |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-11-01
|
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523321001984 |